Imidazotriazines and imidazopyrimidines as kinase inhibitors
Jincong Zhuo, Boothwyn, PA (US); Meizhong Xu, Hockessin, DE (US); Chunhong He, Boothwyn, PA (US); Colin Zhang, Ambler, PA (US); Ding-Quan Qian, Newark, DE (US); David M. Burns, Philadelphia, PA (US); Yun-Long Li, Chadds Ford, PA (US); Brian Metcalf, Moraga, CA (US); and Wenqing Yao, Kennett Square, PA (US)
Assigned to INCYTE HOLDINGS CORPORATION, Wilmington, DE (US); and INCYTE CORPORATION, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US); and Incyte Holdings Corporation, Wilmington, DE (US)
Filed on Jan. 13, 2022, as Appl. No. 17/575,371.
Application 17/575,371 is a continuation of application No. 16/909,686, filed on Jun. 23, 2020, granted, now 11,261,191.
Application 16/909,686 is a continuation of application No. 15/925,996, filed on Mar. 20, 2018, granted, now 10,738,052, issued on Aug. 11, 2020.
Application 15/925,996 is a continuation of application No. 15/016,841, filed on Feb. 5, 2016, granted, now 9,944,645, issued on Apr. 17, 2018.
Application 15/016,841 is a continuation of application No. 13/895,799, filed on May 16, 2013, abandoned.
Application 13/895,799 is a continuation of application No. 12/813,148, filed on Jun. 10, 2010, granted, now 8,461,330, issued on Jun. 11, 2013.
Application 12/813,148 is a continuation of application No. 11/942,130, filed on Nov. 19, 2007, granted, now 7,767,675, issued on Aug. 3, 2010.
Claims priority of provisional application 60/957,236, filed on Aug. 22, 2007.
Claims priority of provisional application 60/861,459, filed on Nov. 29, 2006.
Claims priority of provisional application 60/860,840, filed on Nov. 22, 2006.
Prior Publication US 2023/0002392 A1, Jan. 5, 2023
1. A method of treating lung cancer in a patient in need thereof comprising administering to said patient a therapeutically effective amount of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, or a pharmaceutically acceptable salt thereof.